Peregrine Capital Management LLC Boosts Position in Evolent Health, Inc. (NYSE:EVH)

Peregrine Capital Management LLC increased its holdings in shares of Evolent Health, Inc. (NYSE:EVH - Free Report) by 65.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 503,601 shares of the technology company's stock after purchasing an additional 198,358 shares during the period. Peregrine Capital Management LLC owned 0.43% of Evolent Health worth $5,666,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Wellington Management Group LLP increased its position in Evolent Health by 12.8% in the 3rd quarter. Wellington Management Group LLP now owns 12,595,459 shares of the technology company's stock valued at $356,200,000 after acquiring an additional 1,426,747 shares during the period. Point72 Asset Management L.P. increased its position in Evolent Health by 1,948.5% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,495,385 shares of the technology company's stock valued at $42,289,000 after acquiring an additional 1,422,385 shares during the period. Bellevue Group AG increased its position in Evolent Health by 59.9% in the 3rd quarter. Bellevue Group AG now owns 2,670,050 shares of the technology company's stock valued at $75,509,000 after acquiring an additional 1,000,215 shares during the period. Harbor Capital Advisors Inc. lifted its holdings in shares of Evolent Health by 90.1% during the fourth quarter. Harbor Capital Advisors Inc. now owns 803,211 shares of the technology company's stock worth $9,036,000 after purchasing an additional 380,790 shares during the period. Finally, Foundry Partners LLC acquired a new stake in shares of Evolent Health during the third quarter worth $10,042,000.

Evolent Health Price Performance

Shares of EVH stock traded down $0.27 during trading hours on Friday, hitting $10.44. The company's stock had a trading volume of 5,302,574 shares, compared to its average volume of 2,242,885. The business has a fifty day moving average of $10.77 and a 200-day moving average of $18.92. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of -11.47 and a beta of 1.45. Evolent Health, Inc. has a twelve month low of $9.45 and a twelve month high of $35.00. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58.

Evolent Health (NYSE:EVH - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The technology company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.38 by ($0.35). Evolent Health had a negative net margin of 2.93% and a positive return on equity of 6.30%. The business had revenue of $646.54 million during the quarter, compared to analyst estimates of $650.92 million. As a group, equities research analysts anticipate that Evolent Health, Inc. will post 0.22 EPS for the current year.

Analyst Ratings Changes

EVH has been the subject of several recent research reports. Stephens decreased their price target on Evolent Health from $16.00 to $12.00 and set an "equal weight" rating for the company in a report on Tuesday, January 21st. Royal Bank of Canada dropped their price target on shares of Evolent Health from $20.00 to $17.00 and set an "outperform" rating on the stock in a research note on Tuesday, January 14th. UBS Group dropped their price target on shares of Evolent Health from $27.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, January 16th. BTIG Research dropped their price target on shares of Evolent Health from $36.00 to $29.00 and set a "buy" rating on the stock in a research note on Tuesday, December 3rd. Finally, Truist Financial reduced their price target on Evolent Health from $20.00 to $15.00 and set a "buy" rating for the company in a report on Wednesday, January 22nd. One investment analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $17.79.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.